期刊文献+
共找到1,067篇文章
< 1 2 54 >
每页显示 20 50 100
Imipenem/cilastatin-induced acute eosinophilic pneumonia:A case report
1
作者 Gautam Jesrani Samiksha Gupta +2 位作者 Amtoj Singh Lamba Shreya Arora Monica Gupta 《Journal of Acute Disease》 2023年第6期250-253,共4页
Rationale:Acute eosinophilic pneumonia(AEP)is an acute pulmonary illness caused by eosinophilic infiltration of the lung parenchyma.It can happen after using drugs such as daptomycin and minocycline.AEP induced by imi... Rationale:Acute eosinophilic pneumonia(AEP)is an acute pulmonary illness caused by eosinophilic infiltration of the lung parenchyma.It can happen after using drugs such as daptomycin and minocycline.AEP induced by imipenem/cilastatin is a rare condition.Patient’s Concern:A 45-year-old male patient,who previously suffered from a urinary tract infection and treated with imipenem/cilastatin antibiotic,was presented to us with acute respiratory distress,soon after the initiation of the antibiotic.Computed tomography identified pulmonary infiltrates in the upper and middle lung fields and eosinophils were found to account for 36%of differential count of the broncho-alveolar lavage fluid.He also developed peripheral eosinophilia as the disease progressed.Diagnosis:AEP,secondary to imipenem/cilastatin therapy.Interventions:Steroid therapy was administered and imipenem/cilastatin antibiotic was discontinued.Outcomes:The patient improved completely following the therapy and had clear lung fields on follow-up.Lessons:Imipenem/cilastatin is an uncommon cause of AEP and requires close monitoring during therapy. 展开更多
关键词 Acute eosinophilic pneumonia Broncho-alveolar lavage imipenem/cilastatin Pulmonary infiltrate Peripheral eosinophilia
暂未订购
A randomized,controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections 被引量:1
2
作者 侯芳 李家泰 +10 位作者 吴国平 郑波 陈亦芳 顾俊明 王慧玲 霍丽 薛欣 贾长绪 尹永红 田晓峰 任双义 《Chinese Medical Journal》 SCIE CAS CSCD 2002年第12期1849-1854,共6页
Objective To evaluate the efficacy and safety of meropenem in Chinese patients, we conducted a study for the treatment of patients with lower respiratory tract infections, urinary tract infections and other infection... Objective To evaluate the efficacy and safety of meropenem in Chinese patients, we conducted a study for the treatment of patients with lower respiratory tract infections, urinary tract infections and other infections Methods A total of 182 hospitalized patients were enrolled in the study 90 patients received 500 mg meropenem every 12 hours (or 1 g every 12 hours if necessary) and 92 patients received imipenem/cilastatin 500 mg/500 mg every 12 hours (or 1 g every 12 hours if necessary) by intravenous infusion The duration of treatment was 7-14 days for both groups Results Seventy of 90 cases receiving meropenem and 70 of 92 cases receiving imipenem/cilastatin were assessable for clinical efficacy The overall efficacy rates were 90% for the meropenem group and 87% for the imipenem/cilastatin group, and the bacterial eradication rates were 86% in both groups 93 (76%) of 123 strains isolated from patients produced β lactamases Adverse drug reactions were evaluated in 72 cases in the meropenem group and 70 cases in the imipenem/cilastatin group The adverse drug reaction rates were 9 7% and 8 6%, respectively The results showed that there were no statistical differences between these two groups ( P >0 05) Conclusion Meropenem is effective and safe for the treatment of bacterial infections caused mainly by beta lactamase producing strains 展开更多
关键词 meropenem·imipenem/cilastatin·infection
原文传递
Organic anion transporters also mediate the drug–drug interaction between imipenem and cilastatin 被引量:3
3
作者 Yanna Zhu Xiaokui Huo +7 位作者 Changyuan Wang Qiang Meng Zhihao Liu Huijun Sun Aiping Tan Xiaodong Ma Jinyong Peng Kexin Liu 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2020年第2期252-263,共12页
This study aimed to clarify that organic anion transporters(OATs)mediate the drug–drug interaction(DDI)between imipenem and cilastatin.After co-administration with imipenem,the plasma concentrations and the plasma co... This study aimed to clarify that organic anion transporters(OATs)mediate the drug–drug interaction(DDI)between imipenem and cilastatin.After co-administration with imipenem,the plasma concentrations and the plasma concentration-time curve(AUC)of cilastatin were significantly increased,while renal clearance and cumulative urinary excretion of cilastatin were decreased.At the same time,imipenem significantly inhibited the uptake of cilastatin in rat kidney slices and in human OAT1(hOAT1)-HEK293 and human OAT3(hOAT3)-HEK293 cells.Probenecid,p-aminohippurate,and benzylpenicillin inhibited the uptake of imipenem and cilastatin in rat kidney slices and in hOAT1-and hOAT3-HEK 293 cells,respectively.The uptakes of imipenem and cilastatin in hOAT1-and hOAT3-HEK 293 cells were significantly higher than that in mock-HEK-293 cells.Moreover,the K m values of cilastatin were increased in the presence of imipenem with unchanged V max,indicating that imipenem inhibited the uptake of cilastatin in a competitive manner.When imipenem and cilastatin were co-administered,the level of imipenem was higher compared with imipenem alone both in vivo and in vitro.But,cilastatin significantly inhibited the uptake of imipenem when dehydropeptidase-1(DPEP1)was silenced by RNAi technology in hOAT1-and hOAT3-HEK 293 cells.In conclusion,imipenem and cilastatin are the substrates of OAT1 and OAT3.OAT1 and OAT3 mediate the DDI between imipenem and cilastatin.Meanwhile,cilastatin also reduces the hydrolysis of imipenem by inhibiting the uptake of imipenem mediated by OAT1 and OAT3 in the kidney as a complement. 展开更多
关键词 imipenem/cilastatin Renal DIPEPTIDASE Organic ANION transporters Drug-drug interaction
暂未订购
静脉注射用Primaxin亚胺硫霉素(imipenem)——脱氢肽酶抑制剂(cilastatin)钠盐
4
作者 宋前流 《医药导报》 CAS 1989年第3期45-46,共2页
致爱好医学翻译的朋友们:想辟这个专栏,为时已久,原因是许多读者不断地向我们提出了此项建议。我们辟此新栏有两个目的:让爱好医学英译汉的朋友们有一个相互交流和彼此学习的园地;让所有的读者从译文中获得新的医药新知。请广大译者本... 致爱好医学翻译的朋友们:想辟这个专栏,为时已久,原因是许多读者不断地向我们提出了此项建议。我们辟此新栏有两个目的:让爱好医学英译汉的朋友们有一个相互交流和彼此学习的园地;让所有的读者从译文中获得新的医药新知。请广大译者本着这两个目的,向我们提供英汉对照的稿件。谢谢! ·编者· 展开更多
关键词 亚胺硫霉素 Primaxin cilastatin imipenem 英汉对照 肽酶 青霉 内酞胺 常用量 肌阵挛
暂未订购
利奈唑胺联合亚胺培南西司他丁辅助常规抗结核疗法治疗肺结核合并重症肺炎临床研究
5
作者 李娅敏 成松 +3 位作者 孙景坤 张礼营 彭乐 袁苗 《中国药业》 2026年第1期99-103,共5页
目的探讨利奈唑胺联合亚胺培南西司他丁辅助常规抗结核疗法治疗肺结核合并重症肺炎的临床疗效与安全性。方法选取医院结核科与重症监护室2020年1月至2024年3月收治的肺结核合并重症肺炎住院患者312例,按随机数字表法分为对照组和观察组,... 目的探讨利奈唑胺联合亚胺培南西司他丁辅助常规抗结核疗法治疗肺结核合并重症肺炎的临床疗效与安全性。方法选取医院结核科与重症监护室2020年1月至2024年3月收治的肺结核合并重症肺炎住院患者312例,按随机数字表法分为对照组和观察组,各156例。对照组患者采用常规抗结核疗法联合亚胺培南西司他丁治疗,观察组患者在对照组治疗基础上加用利奈唑胺。两组患者均连续治疗2周,随访12个月。结果观察组治疗总有效率为85.90%,细菌清除率为88.46%,1年生存率为92.31%,分别显著高于对照组的77.56%,64.74%,85.26%(P<0.05)。免疫功能动态监测示,观察组患者治疗1周、2周后的T淋巴细胞CD_(3)^(+),CD_(4)^(+),CD_(4)^(+)/CD_(8)^(+)升高幅度均显著大于对照组同期(P<0.05);观察组患者治疗1周、2周后的CD_(8)^(+)、降钙素原、C反应蛋白、白细胞介素6降低幅度均显著大于对照组同期(P<0.05),观察组患者的中性粒细胞计数在治疗1周后显著回升(P<0.01)。治疗1周后,对照组患者的丙氨酸氨基转移酶及肌酐清除率均显著升高(P<0.05),但组间无显著差异(P>0.05)。观察组与对照组患者不良反应发生率相当(4.49%比3.85%,P>0.05)。结论利奈唑胺联合亚胺培南西司他丁辅助常规抗结核疗法治疗肺结核合并重症肺炎的临床疗效良好,展现了强效协同抑菌的特性,在促进机体免疫功能恢复及减轻炎性损伤方面优势明显,且安全性较好。 展开更多
关键词 利奈唑胺 亚胺培南西司他丁 肺结核 重症肺炎 抗病毒 免疫功能 T淋巴细胞亚群 临床疗效
暂未订购
高效超广谱抗菌新药Imipenem 被引量:4
6
作者 朱峰 张永信 《国外医药(抗生素分册)》 CAS 北大核心 1991年第6期436-440,共5页
Imipenem(IPM)系硫霉素第一个高效衍生物,是新型的β-内酰胺类超广谱抗生素,对临床几乎所有重要致病菌均具有强大抗菌作用,对酶高度稳定,与其它抗菌药几乎无交叉耐药性,具有持续的抗生素后效作用(PAE),且体内分布广、不良反应少。IPM在... Imipenem(IPM)系硫霉素第一个高效衍生物,是新型的β-内酰胺类超广谱抗生素,对临床几乎所有重要致病菌均具有强大抗菌作用,对酶高度稳定,与其它抗菌药几乎无交叉耐药性,具有持续的抗生素后效作用(PAE),且体内分布广、不良反应少。IPM在体内经近端肾小管细胞刷状缘的去氢肽酶Ⅰ代谢灭活,其分解产物对某些动物肾小管有一定毒性反应。临床上将本品与肾去氢肽酶Ⅰ抑制剂Cilastatin按1∶1制成复方制剂(Primaxin或Tienam)应用,可阻断本品在肾脏的代谢和增加泌尿道中原型浓度,并消除其单用可能生产的肾毒性。IPM/Cilastatin在临床上经验治疗各种严重的多重耐药菌感染、多种细菌(需氧菌和厌氧菌) 展开更多
关键词 imipenem 抗菌药 高效 广谱
暂未订购
Imipenem与其他15种抗菌药物对厌氧菌的体外抗菌活性比较 被引量:2
7
作者 王宇倩 朱德妹 +2 位作者 吴培澄 张婴元 刘裕昆 《中国抗生素杂志》 CAS CSCD 北大核心 1993年第1期50-54,共5页
本文报道Imipenem对93株各类厌氧菌的体外抗菌活性并与甲硝唑等15种抗菌药物的体外抗厌氧菌活性比较。结果示Imipenem对包括脆弱类杆菌在内的所有受试厌氧菌均具有强大的抗菌活性,远较其他6种受试的β-内酰胺抗生素强,对所有厌氧菌的抗... 本文报道Imipenem对93株各类厌氧菌的体外抗菌活性并与甲硝唑等15种抗菌药物的体外抗厌氧菌活性比较。结果示Imipenem对包括脆弱类杆菌在内的所有受试厌氧菌均具有强大的抗菌活性,远较其他6种受试的β-内酰胺抗生素强,对所有厌氧菌的抗菌活性等于或超过甲硝唑并优于克林霉素。测试的93株厌氧菌中无Imipenem耐药株。由于Imipenem对需氧菌亦具甚强的抗菌活性,因此在治疗严重需氧菌和厌氧菌混合感染时,Imipenem是一个很有用的抗菌药物。 展开更多
关键词 厌氧菌 体外抗菌活性 抗菌素
暂未订购
注射用亚胺培南西司他丁钠对重症肺炎患者IL-6、PCT、IL-8及CRP的影响分析
8
作者 邹敏 《中国现代药物应用》 2026年第5期97-100,共4页
目的 分析在重症肺炎患者的临床治疗方案中应用注射用亚胺培南西司他丁钠的效果。方法 80例重症肺炎患者,以用药方案不同分为对照组和观察组,每组40例。对照组给予注射用舒巴坦钠治疗,观察组给予亚胺培南西司他丁钠治疗。比较两组炎性... 目的 分析在重症肺炎患者的临床治疗方案中应用注射用亚胺培南西司他丁钠的效果。方法 80例重症肺炎患者,以用药方案不同分为对照组和观察组,每组40例。对照组给予注射用舒巴坦钠治疗,观察组给予亚胺培南西司他丁钠治疗。比较两组炎性因子指标、肺部功能及全身反应(Murray肺损伤评分、Marshall器官功能评分)、康复进程和预后转归。结果 治疗后,两组患者C反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、降钙素原(PCT)水平均低于治疗前,且观察组CRP(6.21±0.29)mg/L、IL-6(115.27±5.95)pg/ml、IL-8(8.32±0.45)pg/ml、PCT(0.55±0.11)ng/ml均低于对照组的(12.49±0.32)mg/L、(121.48±0.67)pg/ml、(13.63±0.27)pg/ml、(0.72±0.13)ng/ml(P<0.05)。治疗后,两组患者Murray肺损伤评分、Marshall器官功能评分均低于治疗前,且观察组Murray肺损伤评分(1.14±0.18)分、Marshall器官功能评分(1.57±0.21)分均低于对照组的(1.75±0.16)、(2.57±0.31)分(P<0.05)。观察组退热时间(1.62±0.11)d、咳嗽缓解时间(2.02±0.21)d、重症加强护理病房(ICU)监护时间(4.21±0.11)d、整体住院时间(7.32±0.21)d短于对照组的(2.32±0.21)、(3.02±0.21)、(6.25±0.33)、(10.16±0.11)d(P<0.05)。结论 对重症肺炎患者实施注射用亚胺培南西司他丁钠治疗,可快速抑制炎性反应,减低肺部损伤和全身反应,同时加快发热、咳嗽等的好转,让患者尽早转归。 展开更多
关键词 注射用亚胺培南西司他丁钠 重症肺炎 肾脏代谢 抗生素 血清指标
暂未订购
ROLE OF OUTER MEMBRANE PROTEINS IN IMIPENEM DIFFUSION IN PSEUDOMONAS AERUGINOSA 被引量:2
9
作者 左联 姚天爵 《Chinese Medical Sciences Journal》 CAS CSCD 1999年第1期57-60,共4页
The present study identified the properties of porins in the outer membrane in Pseudomonas aeruginosa,and showed the role of outer membrane in determining imipenem diffusion in Pseudomonas a... The present study identified the properties of porins in the outer membrane in Pseudomonas aeruginosa,and showed the role of outer membrane in determining imipenem diffusion in Pseudomonas aeruginosa The molecular weight of the major outer membrane protein was analyzed by SDS PAGE The purification of the porins in Pseudomonas aeruginosa was achieved by DEAE ion exchange HPLC The purified outer membrane proteins were reconstituted with phosphatidylcholine and dicetylphosphate into membrane vesicles, and were tested by the liposomes swelling method for the diffusion of imipenem The permeability assay showed that OprC (70 kD), OprD 2 (46kD), and OprE(43 kD) were the channel forming proteins But only OprD 2 was thought to be the likely route of imipenem diffusion 展开更多
关键词 Pseudomonas aeruginosa outer membrane imipenem
暂未订购
耐Imipenem的绿脓杆菌 被引量:2
10
作者 Quinn J P 张荣富 《国外医药(抗生素分册)》 CAS 北大核心 1993年第3期192-193,共2页
Imipenem 是第一个碳青霉烯抗生素,具有包括大部分绿脓杆菌在内的异常广谱活性。不幸之处在于本品对绿脓杆菌感染的临床应用,因分离出的耐药绿脓杆菌接近20%而复杂化。此耐药性导致约半数绿脓杆菌感染的治疗失败。此耐药性最重要的微生... Imipenem 是第一个碳青霉烯抗生素,具有包括大部分绿脓杆菌在内的异常广谱活性。不幸之处在于本品对绿脓杆菌感染的临床应用,因分离出的耐药绿脓杆菌接近20%而复杂化。此耐药性导致约半数绿脓杆菌感染的治疗失败。此耐药性最重要的微生物学特点是对其它β-内酰胺类没有交叉耐药性。这与面对用头孢菌素类或青霉素类治疗,产生耐药性时所发现的广谱耐药性适成对照。我们研究了绿脓杆菌临床分离菌的 Imipenem 选择耐药性,并特别提到耐药分离菌特有的47kD外膜蛋白(OMP)的缺失。这些资料不只为其它研究者进一步证实。接着研究了我们所做的碳青霉烯类经由一种独有而特殊的孔蛋白,透过绿脓杆菌外膜的假说。本文描述通过通透性试验。 展开更多
关键词 imipenem 绿脓杆菌 抗药性
暂未订购
Mechanism of imipenem-induced mental disorder: A meta-analysis 被引量:1
11
作者 Zhou-Hong Zhan Jia-Liang Wang +4 位作者 Li-Hong Wang Nan-Nan Shen Xin-Wen Liu Yan-Na Yu Fu-Rong Liu 《World Journal of Psychiatry》 SCIE 2024年第10期1583-1591,共9页
BACKGROUND Imipenem is a highly effective carbapenem antibiotic,which is widely used in the treatment of many serious bacterial infections.At the same time,it can also cause some adverse reactions,mental abnormalities... BACKGROUND Imipenem is a highly effective carbapenem antibiotic,which is widely used in the treatment of many serious bacterial infections.At the same time,it can also cause some adverse reactions,mental abnormalities are the most concerned central nervous system adverse reactions.Different patients respond differently to imipenem,and the effect of imipenem on psychiatric disorders is unclear.Therefore,meta-analysis summarizing the results of multiple previous studies can provide stronger evidence support for clinical guidelines to guide clinical rational use of imipenem to minimize risks.After reviewing the literature published between 2003 and 2017,seven controlled trials with a total of 550 patients were included,with 273 and 277 patients in the control and experimental groups,respectively.The sample size of the study ranged from a minimum of 30 cases to a maximum of 61 cases.Patients in the experimental group were treated with imipenem while the control group was treated with conventional drugs.Meta-analysis showed that the incidence of mental disorders in the experimental group was higher than that in the control group(odds ratio=3.66,95%confidence interval:1.11-12.11,P=0.030);however,there was no significant difference in the incidence of adverse reactions between the two groups(odds ratio=0.05,95%confidence interval:0.00 to 0.10,P=0.060).Funnel diagrams showed that the scattered points of each study were symmetrical and distributed in an inverted funnel shape;therefore,there was no publication bias.CONCLUSION Imipenem can cause mental disorders in patients.However,the low quality of the included literature may have affected the final results.Therefore,it is necessary to conduct a high-quality randomized controlled study with multiple samples to further confirm the mechanism of imipenem-induced mental disorders and provide effective guidance for clinical treatment. 展开更多
关键词 imipenem PSYCHOSIS Drug mechanism Meta analysis Document resource quality
暂未订购
Evaluation of the Synergistic Effect of EDTA-Functionalized Chitosan Nanoparticles on Imipenem Delivery in Pseudomonas aeruginosa Carbapenem-Resistant Strain AG1 被引量:1
12
作者 Marilyn Porras-Gomez Jose Vega-Baudrit +2 位作者 Fernando Garcia Santiago Nunez-Corrales Sergio Madrigal-Carballo 《Journal of Biomaterials and Nanobiotechnology》 2018年第1期64-78,共15页
Metallo-β-lactamases are bacterial zinc-dependent enzymes involved in the hydrolysis of β-lactamic antibiotics representing the main cause of bacterial resistance to carbapenems, drugs of last resort for treating in... Metallo-β-lactamases are bacterial zinc-dependent enzymes involved in the hydrolysis of β-lactamic antibiotics representing the main cause of bacterial resistance to carbapenems, drugs of last resort for treating infections caused by multiresistant bacteria. We elaborated the hypothesis that it is possible to inhibit the enzymatic activity of metallo-β-lactamases by lowering the availability of zinc in the extracellular medium using metal chelating agents such as EDTA carried on nanoparticles. Chitosan, as linear cationic polysaccharide is frequently used in biomedical and pharmaceutical applications, has been studied as a biocompatible encapsulating agent in drug delivery systems and is an ideal transport agent for bioactive molecular complexes in antibiotic applications due to its ability to associate with negatively charged substances. We developed novel nanoparticles using chitosan as a transport matrix for β-lactamic antibiotics. Nanoparticles were synthesized according to the ion gelation method using tripolyphosphate as crosslinking agent. Nanoparticles were functionalized by the adsorption of EDTA, which acts as complexifying agent for Zn2+ ions causing inhibition of metallo-β-lactamases activity. We evaluate the antimicrobial effects of EDTA-functionalized nanoparticles with an imipenem cargo on the clinical isolate P. aeruginosa AG1, a carbapenem-resistant high-risk clone ST-111 carrying both blaIMP-18 and blaVIM-2 metallo-β-lactamases genes. 展开更多
关键词 CHITOSAN EDTA NANOPARTICLES DRUG-RESISTANT imipenem
暂未订购
Characterization of Imipenem Unsusceptible Pseudomonas Aeruginosa Isolates from Inpatients without Carbapenem Treatment
13
作者 Yi-hai Gu Xiao Zhu +6 位作者 Jing-yun Li Jun Zhang Qing-yuan Zhou Yue Ma Chang-qin Hu Shao-hong Jin Sheng-hui Cui 《国际感染病学(电子版)》 CAS 2013年第1期1-5,共5页
Objective To identify the risk factors for imipenem resistance development and transmission of clinical Pseudomonas aeruginosa isolates.Methods Thirty-seven imipenem unsusceptible Pseudomonas aeruginosa isolates colle... Objective To identify the risk factors for imipenem resistance development and transmission of clinical Pseudomonas aeruginosa isolates.Methods Thirty-seven imipenem unsusceptible Pseudomonas aeruginosa isolates collected from patients in absence of carbapenem treatment were characterized by antimicrobial susceptibility test,pulsed field gel electrophoresis(PFGE)and carbapenem resistant mechanism analysis.Results Before the collection of imipenem unsusceptible Pseudomonas aeruginosa isolates,the average time of patients treated with more than one antimicrobial(20.0±9.5 days,n=16)was significantly longer than those treated with only one antimicrobial(12.6±4.4 days,n=21;t-test,Welch,t=-2.9004,P<0.01).And 32 isolates showed resistance to more than 3 classes of antimicrobials.Six PFGE clusters were identified and 26 isolates were grouped into one dominant cluster(C2).An ISpa1328 sequence insertion in oprD was detected in 33 isolates and the function of efflux was observed in all 37 isolates in the presence of a wide spectrum efflux inhibitor.Conclusions Our data demonstrated that exposure to non-carbapenem drug classes,especially fluoroquinolones andβ-lactams,may be important risk factors for the spread of carbapenem resistant Pseudomonas aeruginosa. 展开更多
关键词 Pseudomonas aeruginosa imipenem resistance Carbapenem
暂未订购
注射用亚胺培南西司他丁钠用于儿童的分剂量及稳定性研究 被引量:2
14
作者 张先明 朱增燕 +1 位作者 王文静 杜小换 《中国药房》 北大核心 2025年第1期101-105,共5页
目的考察注射用亚胺培南西司他丁钠(ICS)的分剂量对其主药亚胺培南(IPN)含量一致性的影响以及不同浓度药液的稳定性,为儿童安全、有效使用ICS提供参考。方法3名操作员按照临床儿童常用的2种分剂量方式(以10 mL或20 mL的0.9%氯化钠注射... 目的考察注射用亚胺培南西司他丁钠(ICS)的分剂量对其主药亚胺培南(IPN)含量一致性的影响以及不同浓度药液的稳定性,为儿童安全、有效使用ICS提供参考。方法3名操作员按照临床儿童常用的2种分剂量方式(以10 mL或20 mL的0.9%氯化钠注射液制成ICS初溶药液,自初溶药液中吸取所需药量)制备ICS供试液,平行处理后通过超高效液相色谱-串联质谱联用法测定IPN的含量,根据IPN含量变异系数(CV)<15%判断每组供试液的含量一致性。按照说明书配制ICS供试液X1,再将X1以0.9%氯化钠注射液按1∶1和1∶2体积比稀释后制得供试液X2和X3,分别置于室温[(23.0±0.5)℃]、30℃恒温水浴锅以及2~8℃冰箱内保存,以规定放置温度和时间下测得的IPN质量浓度与初始(0 h)质量浓度之比判断药液稳定性(比值≥90%则认为药液稳定)。结果每位操作员以2种分剂量方式制得的每组药液中,IPN含量的CV均小于15%,表明IPN的含量偏差较小。3个质量浓度水平的药液在室温6 h或冷藏18 h条件下均较稳定;在30℃放置6 h时,供试液X1和X2也可保持稳定,但供试液X3中IPN的质量浓度较0 h时的质量浓度下降约20%。结论ICS在儿童常用的2种分剂量方式下,其主药IPN的含量一致性较好。ICS药液的稳定性受浓度、温度和时间的影响,更低的浓度在更高的温度下会导致IPN的稳定性降低。临床应注意控制医嘱溶媒量以及配制和使用过程中的环境温度与时间。 展开更多
关键词 注射用亚胺培南西司他丁钠 亚胺培南 分剂量 儿童 稳定性
暂未订购
Detection of the Relationship between Imipenem Susceptible and Non-Susceptible Clinical Isolates of Acinetobacter Baumannii by Repetitive Element PCR-Mediated DNA Fingerprinting in an Egyptian Hospital
15
作者 Soheir Helal Mona M.A. Haleim Maha Oaafar 《Journal of Life Sciences》 2011年第1期59-65,共7页
In this work, the authors aimed to detect the clonal relatedness of the isolated imipenem-susceptible and non-susceptible Acenitobacter baumanii. This study was conducted from September 2008 through August 2009 in Abo... In this work, the authors aimed to detect the clonal relatedness of the isolated imipenem-susceptible and non-susceptible Acenitobacter baumanii. This study was conducted from September 2008 through August 2009 in Aboelreech-Elmounira paediatric-Cairo University-teaching hospital in Egypt. All the isolated acenitobacter species were identified by standard laboratory procedures. The clonal relationship of the A. baumanii (the most common detected clinical type) was studied by biotyping and AST and then confirmed using rep-PCR with primers aimed at repetitive extragenic palindromic sequences and enterobacterial repetitive intergenic consensus sequences. A total of 100 A. baumanii isolates out of 104 acenitobacter species were recovered from different clinical samples. Sixty two percent of the isolates were resistant to imipenem. The resulting rep-PCR patterns oftheA, baumanii strains revealed 8 clones, 3 clones found in the imipenem resistant group, and 5 clones in imipenem sensitive group with statistically significant clonal distribution in both groups (P-value 0.00). Clonality was proved in imipenem resistant group with an alarming predominance of clone 1 representing 80.6% of IMP-R isolates. In accordance the prevalence of resistant acenitobacter strains seems to be correlated with inappropriate antibiotic use. These results call for strict compliance of coordinated strategy of infection control measures and judicious use of antimicrobials which is likely to effectively deal with this serious public health issue. 展开更多
关键词 Acinetobacter baumanii fingerprinting REP-PCR imipenem resistant.
在线阅读 下载PDF
两个集采碳青霉烯类药品治疗肺炎的真实世界疗效比较
16
作者 李平 谢少玲 +1 位作者 叶飞强 张镇彬 《中国处方药》 2025年第17期7-10,共4页
目的随着国家药品集中采购政策的深入实施,美罗培南和亚胺培南西司他汀作为首批纳入集采的碳青霉烯类抗菌药物,其临床可及性显著提高,但仿制药间的真实世界疗效差异缺乏高质量证据。方法本研究基于某三甲医院2024年住院肺炎患者的电子... 目的随着国家药品集中采购政策的深入实施,美罗培南和亚胺培南西司他汀作为首批纳入集采的碳青霉烯类抗菌药物,其临床可及性显著提高,但仿制药间的真实世界疗效差异缺乏高质量证据。方法本研究基于某三甲医院2024年住院肺炎患者的电子病历数据,采用回顾性队列设计和倾向得分匹配(PSM)方法,系统比较集采美罗培南(n=151)与亚胺培南西司他汀(n=138)的疗效差异。结果美罗培南组中高危肺炎(CPIS≥7)有效率优于亚胺培南组(75.8%vs.51.9%,P=0.003);美罗培南组的治疗总有效率高于亚胺培南组,但两组比较差异无统计学意义(77.5%vs.68.1%,P=0.073)。通过PSM控制基线差异后(匹配111对病例),美罗培南优势进一步扩大(有效率差异10.87%,P=0.084)。结论亚组分析表明,美罗培南对耐药菌感染和重症肺炎可能更具临床价值。本研究为集采政策下碳青霉烯类药物的合理选择提供了循证依据。 展开更多
关键词 国家药品集中采购 美罗培南 亚胺培南西司他汀 肺炎 倾向得分匹配 真实世界研究
暂未订购
基于真实世界数据的美罗培南与亚胺培南西司他丁钠治疗重症肺炎临床疗效、安全性和经济学评价
17
作者 李红桥 夏雯 +2 位作者 李兰 黄文泽 饶志威 《中国药业》 2025年第16期104-107,共4页
目的为临床重症肺炎(SP)患者合理使用美罗培南(MEM)和亚胺培南西司他丁钠(ICS)提供参考。方法选取2023年1月1日至2024年6月30日在黄石市中心医院住院期间使用MEM或ICS的SP患者545例,按治疗方法的不同分为观察组(予注射用亚胺培南西司他... 目的为临床重症肺炎(SP)患者合理使用美罗培南(MEM)和亚胺培南西司他丁钠(ICS)提供参考。方法选取2023年1月1日至2024年6月30日在黄石市中心医院住院期间使用MEM或ICS的SP患者545例,按治疗方法的不同分为观察组(予注射用亚胺培南西司他丁钠治疗,161例)和对照组(予注射用美罗培南治疗,257例),进一步行倾向性评分匹配后各纳入158例。比较两组患者综合疗效(含临床疗效、微生物学结果和影像学表现)和药品不良反应(ADR)发生情况,并使用成本-效果分析进行药物经济学评价。结果观察组临床治愈率、影像学好转率、微生物清除率、痊愈率分别为89.87%,92.41%,89.24%,89.24%,显著高于对照组的81.01%,85.44%,76.58%,76.58%(P<0.05)。观察组ADR发生率为3.16%,与对照组的2.53%相当(P>0.05)。观察组相较对照组平均每例患者可节约成本2251.84元,增量成本-效果比为-177.80,敏感性分析结果与之一致。结论MEM和ICS治疗SP患者均有较好的临床效果和安全性,但MEM相比ICS临床疗效更佳,使用成本更低,更具有卫生经济性。 展开更多
关键词 重症肺炎 倾向性评分匹配 美罗培南 亚胺培南西司他丁钠 药物经济学
暂未订购
甲磺酸加贝酯联合亚胺培南西司他丁钠治疗重症急性胰腺炎的疗效及其对肠黏膜与胰腺功能的影响
18
作者 刘向丽 张英 何友新 《临床和实验医学杂志》 2025年第24期2622-2625,共4页
目的探讨甲磺酸加贝酯联合亚胺培南西司他丁钠治疗重症急性胰腺炎(SAP)的疗效及其对肠黏膜与胰腺功能的影响。方法回顾性纳入2022年1月至2025年1月期间在秦皇岛市第二医院治疗的116例SAP患者。按照治疗方案不同分为观察组和对照组,每组... 目的探讨甲磺酸加贝酯联合亚胺培南西司他丁钠治疗重症急性胰腺炎(SAP)的疗效及其对肠黏膜与胰腺功能的影响。方法回顾性纳入2022年1月至2025年1月期间在秦皇岛市第二医院治疗的116例SAP患者。按照治疗方案不同分为观察组和对照组,每组各58例。观察组应用甲磺酸加贝酯联合亚胺培南西司他丁钠治疗,对照组应用亚胺培南西司他丁钠治疗,均连续治疗14 d。比较两组患者的临床疗效、症状改善情况,治疗14 d后的肠黏膜功能指标[D-乳酸、二胺氧化酶(DAO)]、胰腺功能指标[葡萄糖、淀粉酶、胰蛋白酶原-2(TPS-2)]水平。结果观察组患者的治疗总有效率为94.83%,明显高于对照组(82.76%),差异有统计学意义(P<0.05)。观察组患者的腹痛缓解时间、肠鸣音恢复时间、首次排气排便时间、住院时间分别为(3.61±0.89)、(3.12±0.75)、(3.45±0.83)、(11.47±1.86)d,均明显短于对照组[(4.72±1.03)、(3.98±0.87)、(4.35±0.91)、(14.26±2.11)d],差异均有统计学意义(P<0.05)。治疗14 d后,观察组D-乳酸、DAO水平分别为(9.85±1.73)mg/L、(2.69±0.14)U/L,均明显低于对照组[(12.07±1.98)mg/L、(3.74±0.68)U/L],差异均有统计学意义(P<0.05)。治疗14 d后,观察组的血糖、淀粉酶和TPS-2水平分别为(5.81±1.73)mmol/L、(65.41±3.35)U/L、(9.15±2.18)ng/mL,均明显低于对照组[(6.92±1.86)mmol/L、(87.39±5.43)U/L、(18.72±2.33)ng/mL],差异均有统计学意义(P<0.05)。结论与亚胺培南西司他丁钠治疗相比,甲磺酸加贝酯联合亚胺培南西司他丁钠治疗SAP,能明显提高临床疗效,有效缓解患者症状,缩短住院周期,改善肠黏膜屏障功能,减轻胰腺损伤,促进胰腺功能恢复。 展开更多
关键词 急性胰腺炎 甲磺酸加贝酯 亚胺培南西司他丁钠 肠黏膜功能 胰腺功能
暂未订购
治疗VAP doripenem可能优于imipenem
19
《国外药讯》 2009年第2期30-30,共1页
发表在美国胸科医师学会2008年度会议上的一份成本-效益分析显示,凭经验使用doripenem治疗绿脓假单胞菌呼吸机相关性肺炎(VAP)可能优于用亚胺培南(imipenem)。
关键词 DORIPENEM imipenem 治疗 VAP 美国胸科医师学会 呼吸机相关性肺炎 成本-效益分析 绿脓假单胞菌
暂未订购
大蒜素与亚胺培南联用对耐碳青霉烯类肺炎克雷伯菌的体外抑菌效果 被引量:1
20
作者 周惠敏 马军 +4 位作者 沈进 米瑞 杨茜云 刘庆阳 王秋波 《中国热带医学》 北大核心 2025年第1期103-109,共7页
目的评价大蒜素与亚胺培南联合用药对于临床分离的耐碳青霉烯类肺炎克雷伯菌(carbapenem resistant Klebsiella pneumoniae,CRKP)的体外联合抗菌效应,为进一步动物体内药效学研究提供参考。方法根据临床药敏结果纳入22株CRKP作为实验对... 目的评价大蒜素与亚胺培南联合用药对于临床分离的耐碳青霉烯类肺炎克雷伯菌(carbapenem resistant Klebsiella pneumoniae,CRKP)的体外联合抗菌效应,为进一步动物体内药效学研究提供参考。方法根据临床药敏结果纳入22株CRKP作为实验对象。拉丝试验和碳青霉烯抑制增强试验鉴定CRKP的高黏附性及β-内酰胺酶的酶型。运用零交互效价(zero interaction potency,ZIP)方法预测大蒜素和亚胺培南的药物联合作用。使用琼脂纸片扩散法分别检测大蒜素、亚胺培南及大蒜素联合亚胺培南对CRKP的体外抗菌效果。用大蒜素和亚胺培南联合检测CRKP抑菌圈直径和最低抑菌浓度(minimal inhibitory concentration,MIC)。采用结晶紫半定量法观察大蒜素联合亚胺培南对CRKP生物膜形成的影响。结果22株CRKP中高黏附性有6株(27.27%),碳青霉烯抑制增强结果显示22株CRKP菌株均为产A类β-内酰胺酶。大蒜素对CRKP有较强的杀菌作用。根据单因素方差分析结果显示,大蒜素联合亚胺培南的抑菌圈直径(15.91±2.76)mm明显高于单独使用亚胺培南组(8.23±3.46)mm(F=46.39,P<0.001)。通过ZIP和MIC法证明大蒜素和亚胺培南联用,以相加作用为主。利用单因素方差分析结晶紫吸光度值,与对照组(0.213±0.056)相比,大蒜素联合亚胺培南组CRKP生物膜总量(0.134±0.045)降低(F=3.211,P=0.045)。结论体外抑菌试验结果显示,大蒜素与亚胺培南联用后能显著提高亚胺培南对CRKP的抑菌能力,并可有效抑制生物膜形成。 展开更多
关键词 大蒜素 亚胺培南 肺炎克雷伯菌 联合药敏 生物膜
原文传递
上一页 1 2 54 下一页 到第
使用帮助 返回顶部